MétaCan
Menu
← Back to cohort

Application of artificial intelligence (AI) features of nuclear morphology from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with MIBC undergoing cystectomy.

2024· article· en· W4391303315 on OpenAlexaff
Kamal Hammouda, Shilpa Gupta, Tilak Pathak, Guru Sonpavde, Ewan A. Gibb, Sumati Gupta, Benjamin L. Maughan, Neeraj Agarwal, Bradley A. McGregor, Matthew Mossanen, C. Marcela Díaz‐Montero, Peter C. Black, Christopher Weight, Tuomas Mirtti, Badrinath R. Konety, Anant Madabhushi

Bibliographic record

VenueJournal of Clinical Oncology · 2024
Typearticle
Languageen
FieldMedicine
TopicBladder and Urothelial Cancer Treatments
Canadian institutionsUniversity of British Columbia
Fundersnot available
KeywordsMedicineGemcitabineCystectomyBladder cancerNivolumabCisplatinOncologyInternal medicineClinical endpointBiomarkerChemotherapyUrologyCancerImmunotherapyClinical trial

Abstract

fetched live from OpenAlex

674 Background: BLASST-1 is a multi-center phase II trial evaluating neoadjuvant nivolumab (N) with gemcitabine-cisplatin (GC) for patients (pts) with MIBC undergoing radical cystectomy (RC) (NCT03294304). 41 pts with MIBC (cT2-T4a, N≤1, M0) were enrolled between Feb 2018 and June 2019; (cT2N0 90%, cT3N0 7%, cT4N1 3%). Pts received C (70mg/m2) IV on D1, G (1000mg/m2) on D1, D8, and N (360 mg) IV on D8 every 21 days for 4 cycles followed by RC within 8 wks. The primary endpoint was pathologic downstaging (PaR; ≤pT1N0). Safety, Relapse-free survival (RFS), Progression-free survival (PFS) and biomarker analyses were secondary endpoints. PaR rate was 65.8%, the pCR (≤pT is N0) rate was 49% and there were no safety concerns or delays to RC. Morphometric characteristics of the cell nucleus can be used to assess bladder cancer grading and gain insights into cellular functionalities. In this study, we sought to evaluate the ability of the AI model to identify non-responders to neoadjuvant chemo-immunotherapy. in the BLASST-1 cohort based on computerized image features of nuclear morphology and architecture on pre-treatment transurethral resection of bladder tumor (TURBT) tissues. Methods: Of the 41 pts, we had H&E images available for 34 pts, of which 23 had PaR and 11 did not have PaR and these were classified as responder (R) and non-responder (NR) groups. A machine learning model (U-net) was developed and invoked for tumor segmentation on the H&E images from the BLASST-1 cohort. A second machine learning model (HoVer-Net) was employed to segment and classify individual nuclei. A total of 408 features relating to the textural and spatial arrangement of individual cancer nuclei were extracted. The 17 most significant features, identified through the least absolute shrinkage and selection operator, were used to train a Cox regression model to predict the risk of death using 361 MIBC pts from the Cancer Genome Atlas (TCGA). This Cox model was then applied to assign a risk score to pts in BLASST-1, using a threshold learned from TCGA pts, the individual pts in BLASST-1 were assigned as either low-risk or high-risk. Results: The top identified prognostic features described the textural appearance of individual nuclei with more texture. This model accurately predicted PaR in BLASST-1, with an area under a receiver operating characteristic curve of 0.83. Overall, the pts with the same nuclear angle direction within the tumor tissue had a high chance of response to the neoadjuvant chemo-IO combination in the BLASST-1 trial. Conclusions: A computerized AI model relying on nuclear morphologic and architecture features demonstrated prognostic capability in MIBC within the TCGA dataset and predictive capability for the PaR in the BLASST-1 trial. These findings support further validation studies.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.044
GPT teacher head0.395
Teacher spread0.352 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicBladder and Urothelial Cancer Treatments→French-language works237,207→